Moolec Science (MLECW) Operating Margin (2022 - 2024)
Moolec Science (MLECW) posted Operating Margin of 77.92% for Q4 2024, up 42.26% sequentially from 134.97% in Q3 2024, and up 63328.0% YoY from N/an in Q1 2024.
Moolec Science (MLECW) Operating Margin (2022 - 2024) Analysis & Trends
Moolec Science has reported Operating Margin for 3 years, with the latest figure at 77.92% in Q4 2024.
- Quarterly Operating Margin rose 63328.0% year-over-year to 77.92% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 116.72% (down 14997.0% YoY) and the FY2024 annual result came in at 160.76%, up 57443.0% from the prior year.
- Operating Margin grew to 77.92% in Q4 2024 per MLECW's latest filing, from 134.97% in the prior quarter.
- Over five years, Operating Margin peaked at 6246.22% in Q3 2022 and troughed at 63974.35% in Q2 2022.
- A 3-year average of 3939.29% and a median of 87.35% in 2024 frame the typical range for Operating Margin.
- The widest YoY moves for Operating Margin: up 6398769 bps in 2023, down 637655 bps in 2023.
- Over 3 years, Operating Margin stood at 4943.14% in 2022, then tumbled by 114 bps to 711.2% in 2023, then jumped by 89 bps to 77.92% in 2024.
- According to Business Quant data, Operating Margin over the past three periods registered 77.92%, 134.97%, and 193.03% for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -77.92% |
| Sep 30, 2024 | -134.97% |
| Jun 30, 2024 | -193.03% |
| Mar 31, 2024 | -96.78% |
| Dec 31, 2023 | -711.20% |
| Sep 30, 2023 | -130.34% |
| Jun 30, 2023 | 13.34% |
| Mar 31, 2023 | 4,893.20% |
| Dec 31, 2022 | 4,943.14% |
| Sep 30, 2022 | 6,246.22% |
| Jun 30, 2022 | -63,974.35% |
| Mar 31, 2022 | 1,951.15% |